Clinical Trial Update: Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM [Phase 1, Phase 2]

View source ↗

Summary

A safety and dose-ranging study of samalizumab in relapsed or refractory CLL and multiple myeloma was terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• Multiple Myeloma

Drugs mentioned

• Samalizumab (samalizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-03-05